Illuminating function in spatial proteomics

The Naveni® in situ proximity ligation technology makes it possible to visualize and quantify protein-protein interactions, post-translational modifications, and protein localization. The technology is based on dual antibody recognition and signal amplification to increase specificity and sensitivity.

Precise localization of your target with intact tissue morphology

Correct localization of proteins is critical for understanding and treating many diseases. The quality of in situ protein detection assays depends mainly on the specificity of the antibodies used against the target. Pathologists require intact cell and tissue morphology to confirm cancer cell type and origin of metastatic cancer; thus, enzyme-based chromogenic immunohistochemistry (IHC) of formalin-fixed paraffin-embedded tissue is considered to be the “gold standard” for clinical histopathology. But the quality of the IHC method relies largely on single antibodies. Many commercial antibodies have low specificity to the targets, generating unspecific background staining resulting in misleading results. The Naveni™ Proximity Ligation Technology is based on dual antibody recognition, increasing the specificity leading to the correct local precision of the target.

Investigate PD1/PD-L1 interaction and activation in situ

PD1 PD-L1 signaling has with immune checkpoint inhibitors proven to be significant in cancer progression and treatment. Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear.

PD1 activation is an important step in the signaling pathway, yet phosphorylation of PD1 in situ is not well studied, mainly due to lack of specific methods.

Navinci has now developed two Proximity Ligation Assays for the specific detection of the PD1/PD-L1 interaction and phosphorylated PD1 in situ. The PD1/PD-L1 interaction has been verified in several tissues; Hodgkin’s lymphoma, Tonsil, Lung acinar adenocarcinoma, Lung squamous cell carcinoma, Malignant Melanoma, Colon adenocarcinoma and Pancreatic ductal carcinoma, see application examples here.

These products will give deep biological knowledge about the signaling pathways of PD1.